Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain

Last updated: September 5, 2025
Sponsor: Erchonia Corporation
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neurologic Disorders

Neuropathy

Treatment

Erchonia® EVRL™

Clinical Study ID

NCT06912646
R-IPN
  • Ages > 22
  • All Genders

Study Summary

The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of idiopathic neuropathy foot pain in individuals diagnosed with idiopathic neuropathy by a suitably qualified and licensed health professional.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Previously diagnosed with idiopathic peripheral neuropathy by a suitably qualifiedand licensed health professional within the past 6 months.

  • Over the age of 22 years of age

  • Able to read and write English

  • Constant feet pain on-going over at least the past 3 months

  • Subjects using analgesics (pain medication) must be on a stable analgesic regimen (i.e., no changes to the prescribed analgesic regimen) over a period of at least 14days prior to study enrollment; and be willing and able to not have planned upwarddose titration of analgesics during the study period. Decreasing frequency ofanalgesic use during the study is permitted. Cannabis prescribed for medicinalpurposes qualifies as an analgesic in this context

  • Willing and able to refrain from engaging in any non-study therapies for themanagement of foot pain throughout the course of study participation, includingconventional therapies such as physical therapy, occupational therapy, hot or coldpacks, and alternative therapies such as chiropractic care and acupuncture

  • Agrees to refrain from taking a dosage of analgesic (pain medication) for at least 6hours before a scheduled VAS foot pain rating is to be recorded

  • Subject's degree of foot pain on the 0-100 VAS, with "0" being no pain and "100"being worst pain imaginable, is 50 or greater

Exclusion

Exclusion Criteria:

  • Diabetic, referred to as having hemoglobin A1c (HbA1C) of 6.5% or higher

  • Previously diagnosed with any definitive (i.e. not idiopathic) cause of peripheralneuropathy by a suitably qualified and licensed health professional within the past 6 months, such as diabetes, injury, infection, toxins and poisons, alcoholism,medications such as chemotherapy, autoimmune disorders, etc..

  • Pregnant or possibly pregnant, breastfeeding, or planning pregnancy during theintended course of study participation

  • Open wounds (sores, cuts, ulcers, etc.) on or around the treatment area on the feet

  • Cancerous growths or lesions on or around the treatment area on the feet

  • Difficulty with hand dexterity sufficient to negatively impact the ability toadminister treatments with the laser such as from severe arthritis in the hands,Multiple Sclerosis, Cerebral Palsy, Parkinson's Disease, Huntington's Disease, etc.

Study Design

Total Participants: 32
Treatment Group(s): 1
Primary Treatment: Erchonia® EVRL™
Phase:
Study Start date:
May 01, 2025
Estimated Completion Date:
June 16, 2027

Study Description

This clinical study is a single-arm, active treatment group only, non-inferiority prospective design to evaluate the efficacy of the Erchonia® EVRL™ for prescription home use application in providing temporary relief of foot pain due to idiopathic peripheral neuropathy. There will be a single active treatment only subject group in this study. All enrolled subjects will self-administer the treatments with the active (true) Erchonia® EVRL™ laser in his or her own home.

Connect with a study center

  • Franco & Co

    Miramar 4164601, Florida 4155751 33025
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.